Improved Mental and Motor Development During 3 Years of GH Treatment in Very Young Children With Prader-Willi Syndrome (JCEM 2018)

A prospective cohort study showing Improved Mental and Motor Development During 3 Years of GH Treatment in Very Young Children With Prader-Willi Syndrome.

Read More

Update on Multiple Endocrine Neoplasia Type 2: Focus on Medullary Thyroid Carcinoma (J Endo Soc 2018)

Read More

Hypothalamic–Pituitary and Growth Disorders in Survivors of Childhood Cancer: An Endocrine Society Clinical Practice Guideline

Short Stature/Impaired Linear Growth GHD Central Precocious Puberty Hypogonadotropic Hypogonadism Central Hypothyroidism ACTH deficiency  

Read More

Cystic Fibrosis-Related Diabetes (CFRD) ISPAD Clinical Practice Consensus Guidelines

Updated ISPAD guidelines on pathophysiology, diagnosis, clinical course and management of Cystic-fibrosis Related Diabetes. These talk about the role of glucose tolerance tests, hemoglobin A1c, continuous…

Read More

Endocrine Late-Effects of Childhood Cancer and its Treatments

Read More

ASMBS Pediatric Metabolic and Bariatric Surgery Guidelines, 2018

Read More

Hypothalamic Obesity: Prologue and Promise (HRP 2019)

Etiology as well as past/current treatment approaches in the categories of hyperinsulinism, surgical approaches, and targeting energy expenditure/anorectic drugs.

Read More

Balancing the Benefits and Harms of Thyroid Cancer Surveillance in Survivors of Childhood, Adolescent and Young Adult Cancer: Recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group in Collaboration with the PanCareSurFup Consortium (Cancer Treat Rev. 2018)

Read More

An International Consortium Update: Pathophysiology, Diagnosis, and Treatment of PCOS in Adolescence (HRP 2017)

An International Consortium Update on the Pathophysiology, Diagnosis, and Treatment of Polycystic Ovarian Syndrome in Adolescence,

Read More

Revised D&T Statement on GnRHa and Prolonged QT 2017

PES Drugs and Therapeutics Committee presents a statement on the Risk of Prolonged QT Interval with Gonadotropin Releasing Hormone Agonists.

Read More